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Imported 
Chikungunya 
Infection, Italy
To the Editor: Chikungunya vi-
rus (CHIKV) infection is a self-lim-
iting illness characterized by fever, 
headache, weakness, rash, and arthral-
gia. Some patients have prolonged 
weakness or arthralgia lasting several 
months. In 2006, several Indian Ocean 
states and India had an outbreak of 
CHIKV infection (1,2). During the 
epidemic’s peak, some European and 
American travelers returning from 
these areas were infected (3–6).
Because the foci of Aedes al-
bopictus, 1 of the 2 main vectors of 
CHIKV, are now in Italy and many 
travelers visit CHIKV-epidemic ar-
eas, surveillance for imported cases 
is mandatory in Italy (7). From July 
to September 2006, a total of 17 con-
ﬁ  rmed cases of CHIKV infection were 
observed in travelers at 5 Gruppo di 
Interesse e Studio delle Patologie di 
Importazione (GISPI) centers (Italian 
network of Institutes of Infectious and 
Tropical Diseases). Serologic diagno-
sis was performed with a hemagglu-
tination-inhibition test and conﬁ  rmed 
by a plaque-reduction neutralization 
test (8). Demographic and epidemio-
logic characteristics of these patients 
are reported in the Table.
Cases were distributed through-
out the year with a peak from March 
to May 2006 (n = 10). Nine patients 
(53%) were men. Median age was 
43 years (range 31–66 years). Sev-
eral reasons for travel were reported: 
tourism (64.6%), visits to relatives or 
friends (11.8%), business (11.8%), and 
missionary work (5.9%). One patient 
was a resident in the disease-epidemic 
area. The median exposure time in the 
CHIKV-endemic area for the 15 trav-
elers was 15 days (range 9–93 days) 
(missionary and resident patients were 
excluded). The median delay before 
being seen at a clinic after return was 
2 days (range 0–73 days). Only 7 pa-
tients (41.2%) were hospitalized. The 
remainder were outpatients.
All patients had fever; arthralgia 
(88.2%, n = 15), weakness (70.6%, n 
= 12), headache (11.8%, n = 2), diar-
rhea (11.8%, n = 2), and gum bleeding 
and epistaxis (5.9%, n = 1) were other 
reported symptoms. The median dura-
tion of fever was 5 days (range 2–12 
days). Only 7 of 16 patients (43.8%) 
were still febrile when ﬁ  rst  seen. 
Physical examination showed diffuse 
macular erythematous rash in 13 pa-
tients (76.5%), a similar rate to that 
reported among French travelers (4). 
Hepatomegaly was found in 2 patients 
(11.8%), splenomegaly in 2 (11.8%), 
and peripheral lymphadenopathy in 2 
(11.8%).
Twelve acute-phase patients were 
admitted to the hospital for blood 
testing within 3 days of the initial ex-
amination. In contrast with results of 
other studies, leukopenia and throm-
bocytopenia were uncommon in our 
study. Leukopenia (leukocyte count 
<4,000/μL) was present in 4 patients 
(33.3%) and thrombocytopenia (plate-
let count <150,000/μL) in 1 patient 
(8.3%). This ﬁ  nding may help distin-
guish CHIKV infection from dengue 
fever (4). Anemia (hemoglobin level 
<12 g/dL) was found in only 1 patient 
(8.3%). Alanine aminotransferase 
(ALT) and aspartate aminotransferase 
(AST) determination were available 
for 12 patients. ALT and AST levels 
were elevated (>40 IU/L) in 5 (41.7%) 
and 2 (16.7%) patients, respectively. 
Seven (46.7%) of 15 patients fully 
recovered within 1 month; 8 patients 
(53.3%) reported persistent arthralgia.
Because the GISPI network pro-
vides regional coverage only, the 
number of imported CHIKV cases in 
all of Italy in 2006 was likely higher. 
Moreover, most patients probably did 
not seek medical care, and when they 
did, physicians may have failed to 
recognize the disease because of lack 
of familiarity with it or limited diag-
nostic facilities. Differential diagno-
sis with other arthropodborne viruses 
of the Alphavirus genus (Ross River, 
Barmah Forest, o’nyong nyong, Sind-
bis, and Mayaro viruses) is difﬁ  cult, 
but these are comparatively rare. In 
contrast, dengue and CHIKV epidem-
ics may overlap, and potential patients 
should be screened for both.
The potential risk for introduction 
and establishment of CHIKV reser-
voirs in areas with mosquito vectors 
was discussed in March 2006 by a mul-
tidisciplinary European expert panel 
(9). In Italy, A. albopictus was ﬁ  rst 
recorded in 1990; it has since quickly 
spread across the country. Scattered 
foci are now reported in almost all re-
gions, mainly along the coastal plains, 
from the sea to the inlands, up to an 
altitude of ≈500–600 m (7).
The ability of A. albopictus to 
colonize new areas and its adaptability 
to the mild Italian climate allow vec-
tor populations to be active throughout 
the year (10). The patient is thought to 
be viremic for only 6–7 days (shortly 
before and during the febrile period) 
(6). We were unable to directly assess LETTERS
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viremia levels; however, almost half 
the patients were still febrile on return 
to Italy, which suggests a potential 
risk.
Although the same mosquito is 
a potential vector of dengue, no au-
tochthonous case has been reported 
as yet, despite annual reports of many 
imported dengue cases in Italy. On the 
other hand, the clinical manifestations 
of both conditions are nonspeciﬁ  c, 
and a hypothetical autochthonous case 
would most likely go undiagnosed 
unless a targeted surveillance system 
were established. Prompt reporting of 
imported CHIKV infections is essen-
tial for monitoring of potential risk. 
The possibility of introducing CHIKV 
into Italy cannot be ruled out on the 
basis of current evidence.
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Table. Demographic and epidemiologic data on 17 travelers with chikungunya infection diagnosed in 2006, Italy 
Patient
no. Sex Age, y 
Reason for 
travel
Country of 
origin 
Date of return 
(length of stay, 
d)
Date of first medical 
assessment after 
return (delay, d) 
Last date of 
fever (length of 
fever, d) 
Fever on 
date of 
return?
1* M 32 Business Réunion Feb 23 (93)  Feb 25 (2)  Feb 26 (4)  Yes 
2† F 39 Tourism Mauritius Feb 28 (10)  Feb 28 (0)  Feb 28 (4)  Yes 
3‡ M 46 Tourism Mauritius Mar 7 (10)  Mar 7 (0)  Mar 6 (5)  No
4‡ M 32 Tourism Madagascar Mar 7 (15)  Mar 8 (1)  Mar 4 (4)  No
5§ M 49 Tourism Mauritius Mar 08 (16)  Mar 15 (7)  Mar 4 (5)  No
6‡ M 66 Tourism Madagascar Mar 24 (15)  Mar 24 (0)  Mar 27 (5)  Yes 
7§ M 36 Tourism Mauritius Apr 4 (15)  Apr 5 (1)  Apr 1 (6)  No
8* F 43 Resident Madagascar Apr 10 (–)  Apr 11 (1)  Mar 2 (6)  No
9‡ F 46 Tourism Réunion Jan 30 (16)  Apr 13 (73)  NA  (2)  –
10¶ F 44 Visit relatives  Mauritius Apr 17 (33)  Apr 19 (2)  Apr 7 (12)  No
11‡ F 36 Tourism Mauritius Apr 30 (11)  May 3 (3)  May 3 (3)  Yes 
12‡ M 31 Tourism Réunion Apr 21 (30)  May 4 (13)  Apr 5 (6)  No
13‡ M 44 Visit relatives  Cameroon  May 3 (24)  May 22 (19)  May 7 (6)  Yes 
14* M 35 Tourism Seychelles  May 31 (9)  Jun 1 (1)  Jun 1 (2)  Yes 
15* M 38 Tourism Mauritius May 10 (11)  Jun 12 (2)  May 7 (4)  No
16‡ F 58 Missionary 
work 
Central
African
Republic
Jun 24 (14 y) Jul 10 (16)  Apr 26 (12)  No
17* F 57 Business India Sep 8 (31)  Sep 9 (1)  Sep 10 (4)  Yes 
*GISPI (Gruppo di Interesse e Studio delle Patologie di Importazione) centers: Torino. 
†GISPI center: Udine. 
‡GISPI center: Negrar. NA, not available. 
§GISPI center: Brescia. 
¶GISPI center: Triggiano. LETTERS
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10.   Romi R, Severini F, Toma L. Cold accli-
mation and overwintering of female Aedes 
albopictus in Roma. J Am Mosq Control 
Assoc. 2006;22:149–51.
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Dyella japonica 
Bacteremia in 
Hemodialysis 
Patient
To the Editor: Patients who re-
ceive long-term hemodialysis are at 
great risk for infection (1,2), especial-
ly bacteremia, which may lead to dev-
astating outcomes (3). Environmen-
tal bacteria are commonly recovered 
from dialysis ﬂ  uid, but their contribu-
tion to infection is less evident (4). We 
report a bacteremic episode caused by 
an unusual soil bacterium, Dyella ja-
ponica. The patient was a 69-year-old 
Thai woman who had had end-stage 
renal disease for 8 months and was 
receiving hemodialysis twice a week 
via subclavian double-lumen perma-
nent catheter. Approximately 6 h af-
ter hemodialysis, she became febrile. 
Physical examination showed tem-
perature 38oC, respiratory rate 22/min, 
heart rate 80/min, and blood pressure 
130/60 mmHg. The rest of her exami-
nation was unremarkable and included 
normal state of consciousness, clear 
eyeground (fundus), and absence of a 
heart murmur. Her catheter was intact 
without evidence of exit site or cath-
eter infection.
Two blood samples, 1 each from 
the central line and peripheral line, 
were injected into BACTEC Aero-
bic/F bottles and incubated in the 
BACTEC 9240 system (Becton-Dick-
inson Diagnostic Systems, Sparks, 
MD, USA).  A catheter-related bac-
teremia was suspected, and vanco-
mycin (1 g in intravenous drip) was 
prescribed. Other laboratory ﬁ  ndings 
included a total leukocyte count 14.5 
× 109/L (84% neutrophils, 16% lym-
phocytes), blood urea nitrogen 38 mg/
dL, and creatinine 7.9 mg/dL. Urinal-
ysis results were within normal limits. 
Urine and stool cultures were negative 
for pathogenic bacteria. The catheter 
was not removed for culture. On day 
4 of incubation, both blood cultures 
showed growth, which was then 
placed onto 5% (vol/vol) sheep blood 
agar for subculture and produced deep 
yellow colonies. This uniform, gram-
negative, oxidase-positive bacterium 
was not identiﬁ  able with manual phe-
notypic tests and the API 20NE strip 
(bioMérieux, Durham, NC, USA). It 
was identiﬁ  ed by the Vitek 2 system 
(bioMérieux) and reported to be My-
roides sp. with an excellent conﬁ  dence 
level (98.7% probability).
To further conﬁ  rm the identiﬁ  ca-
tion, we used 16S rDNA analysis. The 
primer pair forward 5′-AGAGTTT
GATCMTGGCTCAG-3′ and reverse 
5′-ACGGYTACCTTGTTACGAC
TT-3′ were used to amplify the 16S 
rDNA by PCR. DNA extraction and 
PCR ampliﬁ   cation were carried out 
as described (5). The sequence of 
16S rDNA amplicon (1,450 bp) was 
determined after electrophoresis and 
performed with the 3100 Genetic 
Analyzer (Applied Biosystems, Foster 
City, CA, USA) according to the man-
ufacturer’s recommendations. The 16S 
rDNA sequence of this isolate (strain 
RB28), deposited in GenBank under 
accession no. DQ984127, was com-
pared with sequences in GenBank by 
using the BLAST algorithm (version 
2.0; National Center for Biotechnolo-
gy Information, Bethesda, MD, USA, 
www.ncbi.nlm.nih.gov/blast). Se-
quence alignment and distance analy-
sis were performed with Lasergene 
software (DNASTAR, Inc., Madi-
son, WI, USA). According to the 16S 
rDNA sequence analysis, our isolate 
belonged to the family Xanthomona-
daceae of the Gamma Proteobacteria 
class; the highest sequence similarity 
(99.2%) was obtained for D. japoni-
ca type strain XD53 (6). In contrast, 
RB28 shared <97% sequence similar-
ity to other species of Dyella and other 
genera in this family (data not shown). 
Organisms within the same species 
should share >97% of 16S rDNA se-
quence similarity (7). Therefore, this 
isolate was identiﬁ  ed as D. japonica. 
The biochemical proﬁ  le of RB28 was 
also most consistent with D. japonica 
(Table). 
MIC values as determined by 
Etest were amikacin 0.75, cefotaxime 
0.064, ceftazidime 0.38, ciproﬂ  oxacin 
<0.002, co-trimoxazole 0.125, genta-
micin 1.5, imipenem and meropenem 
0.25 mg/L. Because of MIC results, 
treatment was changed to ceftazidime 
(1 g intravenously every 8 h). Fever 
abated within a few days without cath-
eter removal. The patient had a com-
plete recovery with no complications. 
Follow-up blood cultures 2 and 4 
weeks after 14 days of treatment were 
negative.
The  Dyella genus comprises 3 
species: D. japonica (6), D. koreensis 
(8), and D. yeojuensis (9). All are soil 
isolates and have been neither isolated 
from clinical samples nor reported to 
cause human infection. Their pathoge-
nicity in humans is unknown. Because 
of its rapid onset after hemodialysis, 
the bacteremia in this patient is thought 
to have been associated with the dialy-
sis procedures. Contaminated dialyz-
ing ﬂ  uid may have been a source for 
the organism, and the permanent cath-
eter was likely to have provided an en-
try. In addition, blood culture bottles 
could have been contaminated by en-
vironmental samples. However, the 
diagnosis of catheter-related infection 
could not be deﬁ  nitive because neither 
catheter tip nor ﬂ  uid was available for 
culture. The severity of D. japonica 
bacteremia was difﬁ  cult to determine 
because the clinical manifestation was 